Open in interactive viewer → charts, metric popovers & call review

VolitionRx: A Finger-Prick Bet on Newborns, Priced at Sixteen Cents on the Dollar

Q3 revenue rose 157%, debt fell by roughly $10 million, and the stock still lost 83% in 90 days — because 'discussions' is not a deal
VNRX · Earnings Call · 2026-11-13

VolitionRx: A Finger-Prick Bet on Newborns, Priced at Sixteen Cents on the Dollar

There is a version of the VolitionRx story where this was a good quarter. Revenue nearly tripled. Operating expenses fell 14%. Headcount is down 28% year over year. The company retired a $7.5 million convertible note, prepaid another $2.4 million of the remaining one, and now owes just $0.7 million. Operating loss narrowed for a second straight quarter. And the equity, per the tape, gave back 83.5% of its value in ninety trading days, from a July 10 peak of $1.35 to something that values the whole company at roughly $2.2 million. That gap is the story. The market is not arguing about the science anymore; it is arguing about the clock.

The Quarter That Looked Fine On Paper

Read the revenue line closely, because the headline overstates the run-rate. Terig Hughes was unusually direct about the composition: Q3 revenue of "approximately $1.6 million" versus $0.6 million a year ago reflected "higher Nu.Q Vet revenues, the result of accelerated deferred revenue recognition." In other words, part of the 157% growth was an accounting decision — a re-look at revenue recognition on the Heska arrangement — not new units in the field. Management repeated, for the third straight call, that revenues "remain fairly uneven and difficult to predict from one quarter to the next" and declined to guide. On a company this small, the difference between $1.6 million of product pull-through and $1.6 million of pulled-forward recognition is existential, not cosmetic.

The cost side is where the quarter genuinely improved. Operating loss narrowed to $3.3 million from $5.1 million, and R&D has been cut hard: R&D spending sits near $3 million a quarter, roughly half the 2023 peak. Cameron Reynolds framed that as a philosophical break, not just austerity: the French government funds the sepsis trial, Mayo funds its own trauma work, Revvity pays for the kits. Volition no longer runs studies; it sells.

What Is Actually New: Newborns, Not Sepsis Beds

The freshest thing on this call has almost no precedent in the prior twelve quarters. Volition signed a letter of intent with Missionpharma — a Danish firm inside the Toyota Tsusho Group that supplies healthcare products to over 100 million patients annually and sells into UN agencies. The critical insight came from those global-health conversations: rather than pitch a broad sepsis assay into resource-constrained markets, pick one discrete, fundable indication. "What they came up with was neonatal sepsis," Reynolds said. "That's brand newly born children and their mothers, and that is the biggest killer of children in the developing world."

That reframing is the commercially interesting move of the quarter, and it is paired with the lateral flow prototype — a finger-prick device that correlated with the CE-marked lab assay in ICU sepsis samples. It is also the first time in a year that management has articulated a market-entry sequence rather than a market size. Notably, when pressed on whether Europe or the developing world matters more, Reynolds did not overreach: the West wins on dollars, the Global South wins on number of tests. That is a more disciplined answer than this name has historically given.

What Quietly Left The Stage

The real information is in the subtractions.

Taiwan is gone. Through the April and August calls, the Taiwan screening program was a standing question — CLIA labs, Taiwanese FDA timelines, first-half-2027 revenue, a named head of Asia. On this call, Taiwan appears as a single clause inside an answer about something else: "we're also working with the Japanese government, the SCRUM program in Taiwan." That is it. The human cancer narrative has been consolidated into French reimbursement for lung cancer, which Reynolds now describes as a "Routine use" question with "about a six-month process" behind a five-year temporary reimbursement. One flagship path shrank so another could be promoted.

Hologic is effectively dead. Hologic was a marquee logo — a co-marketing partner with its own momentum spike in late 2025. Asked directly whether the one-year agreement would convert to something larger, Reynolds was blunt: "not with Hologic, but I think primarily due to their own internal reorganization issues." Werfen and Sysmex got the positive language instead, both "strongly expected" to advance "in the short term." Two of four named partners progressing is a fair outcome; a year ago the framing was four.

The $5 million cat milestone has lost its date. This is the cleanest tell. In April: “we do expect to collect that money this year” — Terig Hughes, Chief Financial Officer (CFO) · 2026-04-01. In May, asked whether the payment had arrived: “We haven't received it yet.” — Terig Hughes, Chief Financial Officer · 2026-05-15 On this call, the feline paper is still "expected to subsequently unlock a $5 million contractual milestone payment" — no quarter, no year, no urgency. A catalyst that has slipped three consecutive quarters without a fresh timeline is not a catalyst; it is an open item.

The Pattern That Matters Most

Which brings us to the thing the tape is actually discounting. In August 2025, Reynolds told analysts:

We do believe we are very close to that first human out-licensing deal... I do expect to close the first, which will be a massive milestone for us this quarter.

Cameron Reynolds, Chief Executive Officer · 2025-08-15

Fifteen months later, the language on this call is: "continuing our discussions with more than a dozen of the world's leading diagnostic and liquid biopsy companies." In April, the CEO said he was "quite certain we'll have deals." The count of counterparties has gone up; the count of signed contracts has not. Reynolds has responded by taking operational control — “I have now taken personal direct control of 11 of the most important commercial relationships” — Cameron Reynolds, Chief Executive Officer · 2026-11-13 — and by cutting his own salary by half "until a substantial deal is signed." That is a genuine signal of alignment, and also an admission that the previous structure was not converting.

The Balance Sheet Is The Metronome

Here is why patience is not free. Cash runway stands at roughly 0.6 quarters, down from nearly ten quarters a decade ago. Effective net cash is about negative $5 million. The $2.4 million of quarter-end cash exists because $5.2 million of net ATM proceeds arrived during the quarter. Every month of delay is paid for in shares, at a price already down 83% from July and 99%+ from the 2021 peak.

The stated fix is to get cash burn under $1 million a month in 2027 and to fund the gap non-dilutively — revenue, licensing, grants. That is coherent arithmetic. It requires one signature.

The bull case is not absurd. The French government is running an interventional, real-world trial worth many multiples of Volition's market cap, with Nu.Q NETs as the sole biomarker; the Mayo trauma data showed nucleosome levels 37x healthy in patients who went on to venous thromboembolism; the treatable trait framing for NETosis now spans sepsis, trauma, autoimmune disease and coagulopathy; and Capture-Seq sits in front of multi-billion-dollar MCED and MRD markets with published, patented chemistry. What has never happened is the translation of that optionality into a contract, and the company's own phrase for the platform — repeated across many quarters — remains "potential game changer."

So: a $2.2 million company, down 83% in ninety days, reporting credible cost discipline, a genuinely new and sharper commercial wedge in neonatal sepsis, and a fifteen-month-old promise of a first human license still unfulfilled. The quarter was real progress. The equity says the invoice is due first.